ARVO 2024: A study on multi-ingredient oral supplement for dry eye symptoms and tear volume
May 7th 2024Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.
ARVO 2024: Vision-related activity difficulties in people diagnosed with nAMD and vision impairment
May 6th 2024Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.
ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 5th 2024At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
ARVO 2024: Axial growth after discontinued soft multifocal contact lens wear, BLINK2 study
May 5th 2024David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.
ARVO 2024: 36-month data from the GALE study of pegcetacoplan
May 5th 2024At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.
ASCRS 2024: International data are forthcoming in corneal endothelial disease treatment
April 16th 2024At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.
Oculogenex founder talks about collaboration with NASA and ISS on experiment in macular degeneration
April 11th 2024Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.
ASCRS 2024: 10-year results of using two iStents with cataract surgery
April 9th 2024Paul Harasymowycz, MD, details his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma" from this year's ASCRS meeting in Boston, Massachusetts.